P2Y12 Inhibitors in the Management of Acute Coronary Syndromes

Mark Y Chan, MD, Richard C Becker, MD, Kenneth W Mahaffey, MD, Robert A Harrington, MD, and Matthew T Roe, MD
Duke Clinical Research Institute, Durham, NC, USA

Adenosine diphosphate (ADP)-induced platelet aggregation plays an important role in arterial thrombosis. The P2Y12 receptor that mediates ADP-induced platelet activation and aggregation has become a favored target for the inhibition of platelet aggregation. Currently, clopidogrel is the most widely used P2Y12 inhibitor, but its significant pharmacological limitations have led to the search for alternative P2Y12 inhibitors.
Return to top